Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.
暂无分享,去创建一个
Douglas A. Hosack | R. Lempicki | D. Dimitrov | H. Issaq | J. Metcalf | R. Davey | M. Baseler | J. Adelsberger | J. Kovacs | M. Polis | J. Falloon | H. Masur | H. Lane | M. Di Mascio | I. Sidorov | I. Sereti | R. Stevens | S. Leitman | J. Tavel | G. Kelly | S. Fox | M. Bosche | William Sachau | L. Lambert
[1] R. Lempicki,et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. , 2004, Blood.
[2] J. Metcalf,et al. Increases in CD4+ T Lymphocytes Occur Without Increases in Thymic Size in HIV‐Infected Subjects Receiving Interleukin‐2 Therapy , 2003, Journal of acquired immune deficiency syndromes.
[3] Douglas A. Hosack,et al. A comparison of microLC/electrospray ionization-MS and GC/MS for the measurement of stable isotope enrichment from a [2H2]-glucose metabolic probe in T-cell genomic DNA. , 2003, Analytical chemistry.
[4] E. Wherry,et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.
[5] É. Oksenhendler,et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial , 2003, AIDS.
[6] R. Lempicki,et al. Cutting Edge: L-Selectin (CD62L) Expression Distinguishes Small Resting Memory CD4+ T Cells That Preferentially Respond to Recall Antigen , 2003, The Journal of Immunology.
[7] C. Harley,et al. Cancer cell dynamics in presence of telomerase inhibitors: analysis of in vitro data. , 2002, Journal of theoretical biology.
[8] R. Lempicki,et al. Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] H. Keller,et al. Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy , 2002, AIDS.
[10] H. Lane,et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. , 2002, Controlled clinical trials.
[11] Richard A. Lempicki,et al. Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV , 2001, The Journal of experimental medicine.
[12] Alan S. Perelson,et al. Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy , 2001, The Journal of experimental medicine.
[13] S. Emery,et al. Immunomodulators as adjunctive therapy for HIV-1 infection. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[14] M. Giacca,et al. Changes in thymic function in HIV‐positive patients treated with highly active antiretroviral therapy and interleukin‐2 , 2001, Clinical and experimental immunology.
[15] R. Lempicki,et al. Interleukin‐2 induced immune effects in human immunodeficiency virus‐infected patients receiving intermittent interleukin‐2 immunotherapy , 2001, European journal of immunology.
[16] J. Kovacs,et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. , 2000, The Journal of infectious diseases.
[17] J. Kahn,et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.
[18] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[19] É. Oksenhendler,et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial , 1999, The Lancet.
[20] R. Dewar,et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.
[21] Steven G. Deeks,et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans , 1999, Nature Medicine.
[22] H. Clifford Lane,et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies , 1997, Nature Medicine.
[23] J. Metcalf,et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.
[24] A. Gerber,et al. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections , 1994 .
[25] P. Brambilla,et al. Determination of plasma [6,6-2H2]glucose enrichment by a simple and accurate gas chromatographic-mass spectrometric method. , 1992, Journal of chromatography.